View Post

HHV-6 increases risk of an “idiopathic” pneumonia syndrome after HCT as does murine roseolovirus in a BMT mouse model. Early HHV-6 was also found to increase non-relapse mortality.

In All, Animal Models, Lung Disease, Transplant Complications by Kristin Loomis

Investigators from University of Michigan have demonstrated that murine roseolovirus is a useful homolog for the study of HHV-6 reactivation in lung disease. In a large retrospective study of HCT patients, they also found early HHV-6 reactivation to increase the risk of both idiopathic pneumonia syndrome and non-relapse mortality.

View Post

HHV-6 is by far the most common virus found in the spinal fluid of transplant patients with CNS disorders

In All, Encephalitis & Encephalopathy, Transplant Complications by Kristin Loomis

A 73% of 165 hematopoietic stem cell transplant patients tested for possible encephalitis were positive for HHV-6 in a recent review. Only 10% were positive for EBV and no other virus was positive in more than 3% of cases. The outcome for patients with viral infection was poor with 50% mortality within 6 months and only 30% survival at 5 years.

View Post

HHV-6 is a greater risk than CMV for rejection in pediatric kidney transplantation

In All, Kidney Disease, Transplant Complications by Kristin Loomis

Investigators from the Children’s Hospital of Mexico found that although CMV caused the biggest increase in risk for liver rejection, HHV-6 was the more important infection associated with rejection of kidney transplants. A single HHV-6 infection resulted in an increased risk of over 5 fold, while a coinfection of EBV, HHV-6 and HHV-7 increased the risk of kidney rejection by over 17 fold.

View Post

HHV-6 in Cancer: Does it play a role?

In All, Cancer by Kristin Loomis

Since its discovery, HHV-6 has been studied in the context of lymphoproliferative disorders and various types of cancer. Several obstacles, particularly the ubiquitous nature of the virus, have made it difficult to determine exactly how HHV-6 might, or might not, be involved in tumor development.

View Post

New findings on how HHV-6A/B U94 blocks angiogenesis

In All, Latest Scientific News by Kristin Loomis

The HHV-6 latency gene U94 has been found to block angiogenesis, but the mechanisms behind this phenomenon have been unclear. A team lead by Roberta Rizzo and Elisabetta Caselli in Italy shed light on this process, opening the door to new potential molecular targets to pursue in treating diseases marked by improper vascularization.